Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Nokia (NOK) -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (1203)	12/5/1998 4:53:00 PM
From: gdichaz	Read Replies (1) \| Respond to of 34857

To Mqurice: Yep. My compliments. Spelling ain't my strong suit. :-) Chaz

To: Maurice Winn who wrote (1203)	12/6/1998 1:00:00 PM
From: Dave	Read Replies (1) \| Respond to of 34857

Maurice: You mean you aren't going to respond to this comment: As the analogue base stations are replaced with cdmaOne, Q! will make a lot of money from infrastructure sales and royalties from other infrastructure suppliers. Tero has shown a study where TDMA is growing faster than CDMA, and you agreed. Now, why on earth will a provider replace their Analogue Base Stations with CDMAone when it is clearly apparent that TDMA is growing faster? dave

To: Maurice Winn who wrote (1203)	12/7/1998 9:35:00 AM
From: tero kuittinen	Read Replies (3) \| Respond to of 34857

It's going to be much more hazardous to invest in biotech, Maurice... those products are often billion dollars or bust - type bets for the companies involved. But I'm sure the growth there is going to be spectacular. The old money pharmaceutical companies are already so richly valued that it's probably best to find a half a dozen small start-ups and hope one of them hits the jackpot. I'm really interested in some companies working in angiogenesis inhibition right now - the best way to manage cancer may be to strangle the tumors' blood supply by cutting off creation of new blood vessels. Entremed is apparently curing cancer in mice without breaking a sweat... but how well they can produce the large proteins doing the trick on an industrial scale and whether human trials work out is a complete mystery. Their stock has already see-sawed from 20 to 80 to 20, so it's definitely not for the faint of heart. Don't have the guts to make the leap yet... maybe when the mobile tech starts running out of steam. Tero